RxDoctor Payments Data

Bassel Al-Lahham, MD

Gastroenterology · Phoenix, AZNPI 1619081577

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 32 payments — averaging $68.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$323
  • AbbVie$233
  • E.r. Squibb & Sons, L.L.C.$224
  • Johnson & Johnson$175
  • Ipsen Biopharmaceuticals, Inc$145
  • Madrigal Pharmaceuticals$144
  • plus $958 from 10 others

What the payments were for

  • Food & beverage$2,10295%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,202 in reported general payments places this provider in the 35th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$88,736
Medicare patients
365
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab22$190,738
CreonLipase/Protease/Amylase23$66,315
LinzessLinaclotide52$48,031
Mesalamine11$6,400
Pantoprazole Sodium326$3,155
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine21$1,522
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl83$1,231
Omeprazole47$764
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl43$671
Dicyclomine Hcl23$523
Sucralfate23$491
Esomeprazole Magnesium16$370
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl13$161
Lactulose17$119
Metoclopramide Hcl14$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$233$114,34675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →